Critical Care Medicine
Hypercapnic Acidosis Attenuates Lung Injury Induced by Established Bacterial Pneumonia
Chonghaile, Martina Ni M.B., F.C.A.R.C.S.I.*; Higgins, Brendan D. Ph.D.†; Costello, Joseph M.B., F.C.A.R.C.S.I.*; Laffey, John G. M.D., F.F.A.R.C.S.I.‡
Background: Hypercapnic acidosis protects against lung injury after ischemia–reperfusion, endotoxin-induced and ventilation-induced lung injury. The effects of hypercapnic acidosis in the setting of established pulmonary sepsis are not known. The authors investigated whether hypercapnic acidosis—induced by adding carbon dioxide to inspired gas—would be beneficial or deleterious in established Escherichia coli pneumonia in an in vivo model, in the presence and absence of antibiotic therapy.
Methods: Adult male Sprague-Dawley rats were anesthetized and ventilated. In the first set of experiments, rats were anesthetized, E. coli (5–6.4 × 109/ml colony-forming units) was instilled intratracheally, and the animals were allowed to recover. After 6 h, during which time a severe pneumonia developed, they were reanesthetized and randomly assigned to normocapnia (fraction of inspired carbon dioxide [Fico2] = 0.00, n = 10) or hypercapnic acidosis (Fico2 = 0.05, n = 10). The second set of experiments was performed in a manner identical to that of series 1, but all rats (n = 10 per group) were given intravenous ceftriaxone (30 mg/kg) at randomization. All animals received normocapnia or hypercapnic acidosis for 6 h, and the severity of lung injury was assessed.
Results: In the absence of antibiotic therapy, hypercapnic acidosis reduced the pneumonia-induced increase in peak airway pressure and the decrease in static lung compliance compared with control conditions. In the presence of antibiotic therapy, which substantially reduced lung bacterial counts, hypercapnic acidosis significantly attenuated the extent of pneumonia-induced histologic injury.
Conclusions: Hypercapnic acidosis reduced the magnitude of the lung injury induced by established E. coli pneumonia.
IN patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), “protective” ventilatory strategies improve outcome.1,2
These ventilatory strategies reduce tidal and minute ventilation, and the resultant hypercapnic acidosis (HCA) is permitted to realize the benefits of low lung stretch. However, HCA exerts multiple important effects—potentially beneficial and deleterious—on multiple biologic pathways.3,4
Deliberately induced HCA—by means of added inspired carbon dioxide—is protective in multiple models of lung injury, including ALI induced by free radicals,5
and systemic ischemia–reperfusion,7
pulmonary endotoxin instillation,8
and excessive lung stretch.9,10
Of importance, HCA may have improved outcome in patients who received high stretch mechanical ventilation in the Acute Respiratory Distress Syndrome Network (ARDSnet) tidal volume study.11
The safety of HCA in the setting of live bacterial infection is a significant concern.12,13
ALI and ARDS develop most commonly in the context of severe sepsis,14–19
particularly infection with gram-negative bacilli20–22
such as Escherichia coli
We have previously demonstrated that HCA does not increase the severity of evolving bacterial pneumonia–induced ALI.24
However, in the setting of established bacterial infection, such as pneumonia, the antiinflammatory effects of HCA may result in the impairment of the host response to an invading pathogen, permitting greater bacterial proliferation, and ultimately worsening lung injury.12,13
Given these issues, we wished to test the hypothesis that HCA would worsen ALI induced by an established E. coli bacterial pneumonia in the absence of effective antibiotic therapy. We further hypothesized that this deleterious effect of HCA would be abrogated in the presence of effective antibiotic therapy.
Materials and Methods
Specific pathogen–free adult male Sprague-Dawley rats (300–400 g) were used in all experiments. The experimental model was based on that previously reported by our group, with several modifications.8,24
All work was approved by the Research Ethics Committee of the National University of Ireland, Galway, Ireland, and conducted under license from the Department of Health, Dublin, Ireland.
The E. coli
used in these experiments was of serotype O9 K30 H10 and was supplied by the National Collection of Type Cultures, Central Public Health Laboratory, London, England. The E. coli
were stored on preservative beads (Protect, Lancashire, England) at −80°C. The preparation of the bacterial inoculum has been described in detail previously.24
In brief, beads were placed in 3-ml vials of peptone water (Cruinn Diagnostics, Dublin, Ireland) and incubated at 37°C for 24 h to allow bacterial concentrations to reach a plateau. The bacterial suspension was then centrifuged, washed in phosphate-buffered saline, recentrifuged, and finally resuspended in phosphate-buffered saline to produce the inoculum. The bacterial load in each inoculum was determined by plating serial dilutions on agar plates.
A preliminary series of experiments was performed to determine the bacterial load of intratracheal E. coli
required to produce an established lung injury over a 6-h period. These experiments demonstrated that the intratracheal instillation of an inoculum of 2.5–7.5 × 109
colonies of E. coli
suspended in 0.3 ml phosphate-buffered saline produced a severe established ALI, compared with noninoculated controls within this time frame (table 1
Animals were anesthetized by inhalational induction with isoflurane and an intraperitoneal injection of 40 mg/kg ketamine (Pfizer, Kent, United Kingdom). After confirmation of depth of anesthesia by paw clamp, laryngoscopy was performed (Welch Allyn Otoscope®; Buckinghamshire, United Kingdom), and the animals were intubated with a size 16 intravenous catheter (BD Insyte®; Becton Dickinson Ltd., Oxford, United Kingdom). The inoculum of E. coli bacteria, suspended in 0.3 ml phosphate-buffered saline, was delivered intratracheally. The animals were then allowed to recover and were returned to their cages.
Six hours after bacterial instillation, at which stage a significant lung injury had been demonstrated to develop in pilot studies, the animals were reanesthetized with intraperitoneal 80 mg/kg ketamine and 8 mg/kg xylazine (Vétoquinol, Dublin, Ireland). After confirming depth of anesthesia by absence of response to paw compression, intravenous access was gained via the dorsal penile vein, and anesthesia was maintained with repeated intravenous boluses of Saffan® (0.9% alfaxalone and 0.3% alfadolone acetate; Schering Plough, Welwyn Garden City, United Kingdom). After this, a tracheostomy tube (1-mm ID) was inserted and secured, and intraarterial access (22- or 24-gauge cannulae; Becton Dickinson, Franklin Lakes, NJ) was sited in the carotid artery. Sterile technique was used during all manipulations. After confirmation of the absence of a hemodynamic response to paw clamp, 0.5 mg cisatracurium besylate (GlaxoSmithKline, Dublin, Ireland) was administered intravenously to achieve muscle relaxation, and the lungs were mechanically ventilated (model 683; Harvard Apparatus, Holliston, MA) at a respiratory rate of 80/min, with a tidal volume of 6 ml/kg and positive end-expiratory pressure of 2 cm H2O. To minimize lung derecruitment, a recruitment maneuver consisting of positive end-expiratory pressure at 15 cm H2O for 20 breaths was applied every 15 min throughout the protocol.
After assessment of baseline variables, rats were randomly allocated to receive either normocapnia (fraction of inspired carbon dioxide [Fico2
] = 0.00; fraction of inspired oxygen [Fio2
] = 0.30; fraction of inspired nitrogen [Fin2
] = 0.70) or HCA (Fico2
= 0.05; Fio2
= 0.30; Fin2
= 0.65) and were then subjected to mechanical ventilation for 6 h. An Fico2
of 0.05, which has been demonstrated to produce optimal lung protection without the cardiovascular instability seen at higher Fico2
, was used.7
Depth of anesthesia was assessed every 15 min by monitoring the cardiovascular response to paw clamp, and repeated doses of 0.5 mg cisatracurium besylate were administered at regular intervals throughout the protocol to ensure muscle relaxation. Body temperature was maintained at 36°–37.5°C using a thermostatically controlled blanket system (Harvard Apparatus) and confirmed with an indwelling rectal temperature probe. If at any stage during the protocol the mean arterial blood pressure decreased below 40 mmHg for more than 15 min, the experiment was terminated. When animals fulfilled these termination criteria, the measurements obtained at the end of the previous scheduled hourly interval were taken as final measurements. Heparin (400 U/kg) was administered intravenously, and the animals were then killed by exsanguination.
Series 1 was designed to investigate the effects of HCA in established bacterial pneumonia–induced ALI. After anesthesia and dissection, and commencement on mechanical ventilation, animals were randomly assigned to normocapnia (n = 10) or HCA (n = 10) and ventilated for 6 h.
Series 2 was designed to investigate the effects of HCA on established pneumonia-induced ALI in the presence of effective antibiotic therapy. All animals received 30 mg/kg ceftriaxone (Roche Products Ltd., Welwyn Garden City, United Kingdom) intravenously immediately before randomization to normocapnia or HCA. In all other respects, the protocol was identical to that in series 1. The groups were designated as (1) normocapnia (n = 10) and (2) HCA (n = 10).
Systemic arterial blood pressure, peak airway pressure, and body temperature were measured after animals were cannulated and mechanically ventilated. After 20 min, an arterial blood sample was drawn for blood gas measurement (ABL500; Radiometer, Copenhagen, Denmark). Lung compliance was assessed by measuring static inflation pressure developed in response to the injection of 5 ml air in 1-ml increments. These measurements were repeated at hourly intervals throughout the protocol.
After completion of the 6-h ventilation protocol or when termination criteria were fulfilled, heparin (400 U/kg) was administered intravenously, the animals were exsanguinated during anesthesia, and the heart–lung block was dissected. Blood was centrifuged, and the plasma was snap frozen for similar analysis.
Immediately postmortem, the heart–lung block was dissected from the thorax, and bronchoalveolar lavage (BAL) was performed. BAL was performed by intratracheal instillation of three aliquots (5 ml each) of normal saline and collection of the returned fluid by free drainage. Total leukocyte numbers per milliliter in the BAL fluid were counted, and differential cell counts were performed after staining with Hema-Gurr Rapid Staining set for Hematology (BDH Laboratory Supply, Poole, United Kingdom). Samples of BAL fluid were centrifuged, and the supernatant was snap frozen in liquid nitrogen and stored at −80°C for further analysis. The concentration of bacteria in the BAL fluid was determined by plating serial dilutions on blood agar plates and performing a colony count 24 h later. The concentration of tumor necrosis factor (TNF) α and interleukin (IL) 6 in the BAL was determined using a quantitative sandwich enzyme-linked immunosorbent assay (R&D Systems, Abingdon, United Kingdom) as previously described.25,26
The left lung was isolated and fixed for morphometric examination as previously described.8,24,27
Briefly, the pulmonary artery was cannulated, the left atrium was incised, and the pulmonary circulation was perfused with normal saline at a constant hydrostatic pressure of 35 cm H2
O until the left atrial effluent was clear of blood. The left lung was then inflated through the tracheal catheter using paraformaldehyde (4% wt/vol) in phosphate-buffered saline (300 mOsmol) at a pressure of 25 cm H2
O. Paraformaldehyde was then instilled through the pulmonary artery catheter at a pressure of 62.5 cm H2
O. The left atrium was then tied off to prevent pulmonary venous inflow into the atrium, creating a constant distending pressure across the pulmonary vasculature, and maximally distending the pulmonary vessels. After 30 min, the pulmonary artery and trachea were ligated, and the lung was stored in paraformaldehyde for 24 h and then embedded in paraffin wax.27
The extent of histologic lung damage was determined using quantitative stereologic techniques as previously described.28
Briefly, the vertical axis of each left lung was identified, and the lung was cut perpendicular to this axis into 4-mm-thick slices with a sharp blade beginning at a position chosen by random number within the first slice. These tissue slices were then embedded in paraffin and sections (7 μm) from each slice mounted on slides and stained with hematoxylin and eosin. An image of each complete lung section was captured as previously described.7
A point-counting grid was superimposed on the image of each section to estimate its area, and the number of randomly chosen visual fields sampled from any section was proportionate to its area. Each field was examined under light microscopy (× 10 objective; Leica, Laboratory Instruments, Wetzlar, Germany). The images were acquired as described and then imported into Stereology Toolbox (Morphometrix, Davis, CA) at a final magnification of × 60. The intraacinar tissue was defined as all tissues within the gas exchange portion of the lung, i.e.
, respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli, including blood vessels contained within their walls. The intraacinar airspace was defined as all airspaces within the lumen of respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli. The volume fractions of intraacinar tissue and intraacinar airspace were then determined by the use of a point-counting grid as previously described.28,29
The distribution of all data was tested for normality using the Kolmogorov–Smirnov test. Results are expressed as mean and SD if normally distributed, and as median and interquartile range if nonnormally distributed. Data that were obtained at multiple time points throughout the experiment, such as arterial oxygen and carbon dioxide tension and pH and airway pressures, were analyzed using a two-way repeated-measures analysis of variance, with group allocation (HCA vs. control) as the group factor and time as the repeated measure. Lung histology was analyzed by two-way analysis of variance, with group as the first factor and histologic classification (airspace, intraalveolar tissue, extraacinar tissue) as the second factor. Other data obtained at a single time point were analyzed using a t test or Mann–Whitney U test, with the Bonferroni correction as appropriate. Mortality data were analyzed using a Fisher exact test. A two-tailed P value less than 0.05 was considered significant.
HCA without Antibiotic Therapy
Twenty animals underwent bacterial inoculation. All animals survived bacterial inoculation, developed lung injury, and were entered into the treatment protocol. No animals were excluded after randomization into the study. There were no significant between-group differences in the number of bacteria instilled into each animal (table 2
). Five animals in the control group and four animals in the HCA group survived the complete protocol, indicating a 55% overall mortality in the study. There was no significant between-group difference in mortality rate or in the duration of survival.
Both groups sustained a comparable degree of pneumonia-induced lung injury at entry into the treatment component of the protocol. Specifically, there were no significant differences between the groups at entry to the treatment protocol in regard to lung function as indicated by arterial oxygen and carbon dioxide tension, arterial pH, peak airway pressure, static compliance, and alveolar–arterial oxygen gradient (table 2
and figs. 1–3
Arterial pH and carbon dioxide tension were similar in the normocapnia and HCA groups at baseline (fig. 1A and B
). There was an initial rapid increase in arterial carbon dioxide tension and decrease in pH in the HCA group after alteration of the Fico2
. There were further significant decreases in pH over the course of the protocol in both groups. At the end of the experiment, arterial carbon dioxide tension was significantly higher and pH was significantly lower in the HCA group than in the normocapnia group (fig. 1A and B
). There was no significant between-group difference in serum bicarbonate or in base excess, at entry into or at the end of the protocol (table 2
Arterial oxygen tension decreased to a similar extent in the two groups over the course of the experiment (fig. 2A
). At the end of the protocol, there was no significant difference in alveolar–arterial oxygen gradient, measured on 100% O2
, between the control and HCA groups (table 2
). There was no significant between-group difference in the final alveolar–arterial oxygen gradient, measured after ventilation with Fio2
of 1.0 for 15 min at the end of the experimental protocol (table 2
). Peak airway pressure increased significantly in the normocapnia group over time but was unchanged in the HCA group (fig. 2B
). Static inspiratory lung compliance decreased significantly from baseline in the normocapnia group over time but was unchanged in the HCA group (fig. 3A
). Mean arterial blood pressure decreased significantly in both groups over the course of the treatment protocol (table 2
). There were no significant between-group differences in mean arterial blood pressure over the course of the protocol.
There was no significant difference in BAL neutrophil counts or BAL TNF-α levels in the control group versus
the HCA group (table 2
). Of interest, BAL IL-6 levels were significantly higher in the HCA group (table 2
). Quantitative stereologic analysis demonstrated that there were no significant between-group differences in airspace or tissue fractions (fig. 3B
). There were no significant between-group differences in the bacterial loads in the lungs, as determined by analysis of BAL, or in the blood, at the end of the protocol (table 2
HCA with Antibiotic Therapy
Twenty-four animals underwent bacterial inoculation. All animals survived bacterial inoculation, but four animals died as a result of the development of a severe lung injury before entry into the treatment protocol. Twenty animals were entered into this study. No animals were excluded after randomization into the study. There were no significant between-group differences in the number of bacteria instilled into the animals (table 3
). All animals survived for the entire duration of the treatment protocol in both groups.
The normocapnia and HCA groups sustained a comparable degree of pneumonia-induced lung injury at entry into the treatment protocol. Specifically, there were no significant differences between the groups at entry to the treatment protocol in regard to lung function as indicated by arterial oxygen and carbon dioxide tension, arterial pH, peak airway pressure, static compliance, and alveolar–arterial oxygen gradient (table 3
and figs. 4 and 5
). Although not directly compared, the degree of lung injury at entry into the treatment protocol was greater than that sustained in series 1. This may be because of batch-to-batch animal variation in susceptibility to bacterial infection.
Arterial pH and carbon dioxide tension were similar in the normocapnia and HCA groups at baseline (table 3
). There was an initial rapid increase in arterial carbon dioxide tension and decrease in pH in the HCA group after commencement of inspired carbon dioxide. There were further significant decreases in pH over the course of the protocol in the HCA group but not in the normocapnia group. At the end of the experiment, arterial carbon dioxide tension was significantly higher and pH was significantly lower in the HCA group than in the normocapnia group (table 3
). The serum bicarbonate levels were significantly lower in the HCA group at the end of the protocol (table 3
Arterial oxygen tension increased significantly in both groups over the course of the experiment (fig. 4A
). There were no significant between-group differences in arterial oxygen tension at any point during the protocol. At the end of the protocol, there was no significant difference in alveolar–arterial oxygen gradient, measured at an Fio2
of 1.0, between the control and HCA groups (table 3
). Peak airway pressures did not change significantly in either group over time (fig. 4B
). At the end of the experiment, there was no significant between-group difference in peak airway pressure (fig. 4B
). Static inspiratory lung compliance did not change significantly in either group over time. At the end of the experiment, there was no significant difference in static inspiratory compliance between the normocapnia and HCA groups (fig. 5A
). Mean arterial blood pressure decreased significantly in both groups over the course of the treatment protocol (table 3
). There were no significant between-group differences in mean arterial blood pressure over the course of the protocol.
There was no significant difference in BAL neutrophil counts, BAL TNF-α levels, or BAL IL-6 levels in the in normocapnia group versus
the HCA group (table 3
). Quantitative stereologic analysis demonstrated that there was significantly less histologic injury in the HCA group. The HCA group had a significantly greater alveolar airspace fraction and a significantly reduced alveolar tissue fraction compared with the normocapnia group (fig. 5B
). These data are consistent with a reduced degree of structural lung damage in the HCA group. The numbers of bacteria recovered from the BAL was greatly reduced compared with the animals that received antibiotic therapy. There were no significant between-group differences in the bacterial loads of the lungs, as determined by analysis of BAL. No viable bacteria were present in the bloodstream in any animal from either group (table 3
Deliberately induced HCA has been demonstrated to attenuate ALI in several ex vivo
and in vivo
laboratory models of ALI. In the isolated perfused rabbit lung, HCA attenuates the increase in lung permeability seen after free radical–,5
ALI. HCA has been demonstrated to attenuate the impairment in oxygenation, the deterioration in lung mechanics, and the increase in lung permeability seen after in vivo
ischemia–reperfusion. HCA also directly protects against endotoxin-induced lung injury—a sterile model of sepsis-induced ARDS.8
These and other findings have led to the suggestion that HCA may have potential as a therapy in clinical ARDS.3,12,30
The safety and potential for adverse effects of HCA in the context of live bacterial sepsis is a key issue given prevalence of hypercapnia in patients treated with contemporary lung ventilation strategies. The concern is that HCA may worsen lung damage and injury caused by live bacterial infection.12,13
This issue is of central importance given the prevalence of sepsis as a cause of admission to critical care units,31
the frequency of nosocomial infection in the critically ill,32
and the fact that severe sepsis associated with multiorgan failure remains a leading cause of death in these patients. The basis for this concern is the known antiinflammatory properties of HCA. While these may be advantageous in reducing the extent of host-induced tissue injury in nonsepsis models, its effects during established bacterial replication and proliferation are as yet unknown.
Hypercapnic acidosis may have a differential impact on outcome depending on the phase of the infection process when it is introduced. Bacteria such as E. coli
cause tissue damage through several mechanisms, including toxins, direct bacterial damage, and induction of the host immune response. The significance of each depends on the time course of the infection. Early in the infection process, the contribution of bacterial toxins and the host response to the infection may predominate over direct bacterial injury and damage which occur later. The antiinflammatory effects of HCA3
and its potential to reduce endotoxin-induced ALI8
may thus limit early tissue injury. Our previous finding that HCA does not increase the severity of evolving bacterial pneumonia24
provides reassurance regarding the effects of HCA in early lung infection.
In contrast, HCA may impair the host response to established bacterial sepsis. The phagocytic activity and bactericidal capacity of neutrophils and macrophages is central to an effective host response to invading bacteria. HCA also attenuates free radical activity, which is central to the bactericidal activity of neutrophils and macrophages.6
Therefore, as infection becomes more established, HCA may reduce neutrophil recruitment and microbicidal33,34
and chemotactic activity,35
impairing bacterial killing, leading to increased bacterial load and overwhelming bacterial invasion, ultimately exacerbating tissue damage.12,13
We used a well-characterized animal model of infection-induced lung injury that mimics the clinical development of ARDS very closely.36–40
Intratracheal E. coli
instillation resulted in physiologic and pathologic changes consistent with a significant lung injury at 6 h after bacterial instillation, as evidenced by an overall mortality of 20% before entry into the treatment protocol and the higher airway pressures and lower oxygenation seen at baseline in our animals. These changes were similar to those previously described, and included decrements in lung compliance,40
decreased oxygen exchange,40
and alveolar infiltration of neutrophils.38
This in vivo
model of established pneumonia has direct clinical relevance, particularly in the context of the critically ill patient, where lung infection and injury is generally well established by the time therapy is instituted.
Based on these issues, we hypothesized that HCA would worsen lung injury in the setting of established pulmonary bacterial sepsis in the absence of effective antibiotic therapy. In contrast to our hypothesis, we found that HCA exerted modest protective effects, reducing the decrement in lung static and dynamic compliance compared with normocapnia. Of importance, there was no evidence to suggest that HCA exerted deleterious effects in established sepsis. In particular, there was no evidence that HCA increased BAL or bloodstream E. coli counts, which might have been expected had HCA inhibited bacterial killing.
In this study, we used ceftriaxone, a third-generation cephalosporin with broad spectrum antibacterial effects against both gram-negative and gram-positive organisms and a prolonged elimination half-life. Preliminary laboratory work confirmed that our E. coli
isolate was sensitive, which is in keeping with reports in the literature.41
The administration of ceftriaxone at the time of randomization of the animals to normocapnia or HCA reduced the progression of the lung injury and damage. All animals survived the treatment component of the protocol, which contrasts with a mortality of more than 50% without antibiotics. Furthermore, arterial oxygenation improved and airway pressures were reduced in both groups during the treatment protocol. Of importance, HCA reduced the severity of histologic injury, increasing the alveolar airspace fraction, while reducing alveolar tissue fraction, compared with the group that received normocapnia. There were no between-group differences in the bacterial loads of the lungs, which were greatly reduced compared with those seen in animals that did not receive antibiotic therapy.
Hypercapnic acidosis seems to exert net beneficial effects in the setting of established bacterial pneumonia, both in the presence and in the absence of effective antibiotic therapy. Potential mechanisms underlying these protective effects include reduction of free radical generation5
; decreased oxidant-induced tissue damage8
; attenuation of the concentration of key cytokines, such as TNF-α, IL-1β,42
; and attenuation of cellular immune function.43–45
The beneficial effects of HCA on lung compliance seem to be due to an attenuation of the increase in alveolar tissue and reduction in alveolar airspace seen in control animals in response to established E. coli
infection. Other potential mechanisms, such as alterations in alveolar–capillary permeability46,47
and in surfactant synthesis or function,48
may also play a role in this protective effect.
Hypercapnic acidosis could lead to an increase in bacterial load via
two mechanisms, namely enhancement of bacterial growth or reduced bacterial killing. In regard to the potential for HCA to enhance bacterial growth, the concentrations of carbon dioxide used in this study, and indeed seen clinically, have minimal potential to alter the growth of E. coli
. In fact, the growth rate of E. coli
has been demonstrated to be unaltered by carbon dioxide values greater than 20%, concentrations of carbon dioxide that markedly exceed those used in this study.49
Concerns regarding the potential for HCA to reduce bacterial killing are allayed by the finding that HCA did not increase lung or bloodstream E. coli
counts in this model. Therefore, it seems that the antiinflammatory effects of HCA limited tissue injury in the setting of established bacterial infection but did not lead to an increase in bacterial load, a major potential concern in the clinical setting.
There are a number of aspects of this study that indicate the need for caution before extrapolation to the clinical scenario. First, this study used a concentration of 5% CO2
, which was based on our previous experience that this was both safe and effective.7
This produced a degree of hypercapnia and acidosis observed commonly when using protective ventilatory strategies in intensive care settings. Second, ALI and ARDS generally have time courses significantly longer than the 12 h assessed by this model. Differences between groups that were not apparent at 6 h after institution of HCA might be clear after a number of days. Further experiments with a longer observation period might be useful in giving insights into the likely clinical impact of HCA in infection-induced ARDS. A third limitation is the fact that the degree of lung injury 6 h after bacterial instillation at entry into the treatment protocol was greater in the second compared with the first experimental series. The reasons for this degree of variability, although not uncommon in in vivo
studies, are unclear but may be due to batch-to-batch animal variation in susceptibility to bacterial infection. The use of anesthesia may have altered the degree of lung injury in this model.50
However, the anesthetic regimen was identical in all groups in each series. Finally, the effects of HCA in the setting of lung injury produced by other pathogens that are important in the clinical setting, such as Haemophilus influenzae
remain to be determined.
We have demonstrated potential beneficial effects of HCA in the setting of established pneumonia-induced ALI. The effects of HCA in this setting are seen in the presence and absence of effective antibiotic therapy. Additional experimental work is needed over longer time periods to further clarify the interactions between HCA and pulmonary infection.
1. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301–8
2. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347–54
3. Laffey JG, Kavanagh BP: Carbon dioxide and the critically ill: Too little of a good thing? Lancet 1999; 354:1283–6
4. Lang JD, Chumley P, Eiserich JP, Estevez A, Bamberg T, Adhami A, Crow J, Freeman BA: Hypercapnia induces injury to alveolar epithelial cells via
a nitric oxide-dependent pathway. Am J Physiol Lung Cell Mol Physiol 2000; 279:L994–1002
5. Shibata K, Cregg N, Engelberts D, Takeuchi A, Fedorko L, Kavanagh BP: Hypercapnic acidosis may attenuate acute lung injury by inhibition of endogenous xanthine oxidase. Am J Respir Crit Care Med 1998; 158:1578–84
6. Laffey JG, Tanaka M, Engelberts D, Luo X, Yuan S, Tanswell AK, Post M, Lindsay T, Kavanagh BP: Therapeutic hypercapnia reduces pulmonary and systemic injury following in vivo
lung reperfusion. Am J Respir Crit Care Med 2000; 162:2287–94
7. Laffey JG, Jankov RP, Engelberts D, Tanswell AK, Post M, Lindsay T, Mullen JB, Romaschin A, Stephens D, McKerlie C, Kavanagh BP: Effects of therapeutic hypercapnia on mesenteric ischemia-reperfusion injury. Am J Respir Crit Care Med 2003; 168:1383–90
8. Laffey JG, Honan D, Hopkins N, Hyvelin JM, Boylan JF, McLoughlin P: Hypercapnic acidosis attenuates endotoxin-induced acute lung injury. Am J Respir Crit Care Med 2004; 169:46–56
9. Sinclair SE, Kregenow DA, Lamm WJ, Starr IR, Chi EY, Hlastala MP: Hypercapnic acidosis is protective in an in vivo
model of ventilator-induced lung injury. Am J Respir Crit Care Med 2002; 166:403–8
10. Broccard AF, Hotchkiss JR, Vannay C, Markert M, Sauty A, Feihl F, Schaller MD: Protective effects of hypercapnic acidosis on ventilator-induced lung injury. Am J Respir Crit Care Med 2001; 164:802–6
11. Kregenow DA, Rubenfeld GD, Hudson LD, Swenson ER: Hypercapnic acidosis and mortality in acute lung injury. Crit Care Med 2006; 34:1–7
12. Swenson ER: Therapeutic hypercapnic acidosis: Pushing the envelope. Am J Respir Crit Care Med 2004; 169:8–9
13. Laffey JG, O’Croinin D, McLoughlin P, Kavanagh BP: Permissive hypercapnia: Role in protective lung ventilatory strategies. Intensive Care Med 2004; 30:347–56
14. Zilberberg MD, Epstein SK: Acute lung injury in the medical ICU: Comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998; 157:1159–64
15. Goh AY, Chan PW, Lum LC, Roziah M: Incidence of acute respiratory distress syndrome: A comparison of two definitions. Arch Dis Child 1998; 79:256–9
16. Paret G, Ziv T, Augarten A, Barzilai A, Ben-Abraham R, Vardi A, Manisterski Y, Barzilay Z: Acute respiratory distress syndrome in children: A 10 year experience. Isr Med Assoc J 1999; 1:149–53
17. Valta P, Uusaro A, Nunes S, Ruokonen E, Takala J: Acute respiratory distress syndrome: Frequency, clinical course, and costs of care. Crit Care Med 1999; 27:2367–74
18. TenHoor T, Mannino DM, Moss M: Risk factors for ARDS in the United States: Analysis of the 1993 National Mortality Followback Study. Chest 2001; 119:1179–84
19. Redding GJ: Current concepts in adult respiratory distress syndrome in children. Curr Opin Pediatr 2001; 13:261–6
20. Fein AM, Lippmann M, Holtzman H, Eliraz A, Goldberg SK: The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 1983; 83:40–2
21. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF: Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 1984; 130:791–6
22. Martin MA, Silverman HJ: Gram-negative sepsis and the adult respiratory distress syndrome. Clin Infect Dis 1992; 14:1213–28
23. Markowicz P, Wolff M, Djedaini K, Cohen Y, Chastre J, Delclaux C, Merrer J, Herman B, Veber B, Fontaine A, Dreyfuss D: Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome: Incidence, prognosis, and risk factors. ARDS Study Group. Am J Respir Crit Care Med 2000; 161:1942–8
24. O’Croinin DF, Hopkins NO, Moore MM, Boylan JF, McLoughlin P, Laffey JG: Hypercapnic acidosis does not modulate the severity of bacterial pneumonia-induced lung injury. Crit Care Med 2005; 33:2606–12
25. Moreland JG, Fuhrman RM, Wohlford-Lenane CL, Quinn TJ, Benda E, Pruessner JA, Schwartz DA: TNF-alpha and IL-1 beta are not essential to the inflammatory response in LPS-induced airway disease. Am J Physiol Lung Cell Mol Physiol 2001; 280:L173–80
26. Calkins CM, Bensard DD, Heimbach JK, Meng X, Shames BD, Pulido EJ, McIntyre RC Jr: L-arginine attenuates lipopolysaccharide-induced lung chemokine production. Am J Physiol Lung Cell Mol Physiol 2001; 280:L400–8
27. Howell K, Preston RJ, McLoughlin P: Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol 2003; 547:133–45
28. Hopkins N, Cadogan E, Giles S, McLoughlin P: Chronic airway infection leads to angiogenesis in the pulmonary circulation. J Appl Physiol 2001; 91:919–28
29. Bolender RP, Hyde DM, Dehoff RT: Lung morphometry: A new generation of tools and experiments for organ, tissue, cell, and molecular biology. Am J Physiol 1993; 265:L521–48
30. Hickling KG: Lung-protective ventilation in acute respiratory distress syndrome: Protection by reduced lung stress or by therapeutic hypercapnia? Am J Respir Crit Care Med 2000; 162:2021–2
31. Rubenfeld GD: Epidemiology of acute lung injury. Crit Care Med 2003; 31:S276–84
32. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274:639–44
33. Simchowitz L, Cragoe EJ Jr: Regulation of human neutrophil chemotaxis by intracellular pH. J Biol Chem 1986; 261:6492–500
34. Demaurex N, Downey GP, Waddell TK, Grinstein S: Intracellular pH regulation during spreading of human neutrophils. J Cell Biol 1996; 133:1391–402
35. Rotstein OD, Fiegel VD, Simmons RL, Knighton DR: The deleterious effect of reduced pH and hypoxia on neutrophil migration in vitro
. J Surg Res 1988; 45:298–303
36. Song GW, Robertson B, Curstedt T, Gan XZ, Huang WX: Surfactant treatment in experimental Escherichia coli
pneumonia. Acta Anaesthesiol Scand 1996; 40:1154–60
37. Freeman BD, Correa R, Karzai W, Natanson C, Patterson M, Banks S, Fitz Y, Danner RL, Wilson L, Eichacker PQ: Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli
pneumonia in rats. J Appl Physiol 1996; 80:2066–76
38. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, Banks SM, Eichacker PQ: G-CSF during Escherichia coli versus Staphylococcus aureus
pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999; 159:1377–82
39. Zeni F, Parent C, Correa R, Natanson C, Freeman B, Fontana J, Quezado M, Danner RL, Fitz Y, Richmond S, Gerstenberger E, Banks SM, Eichacker PQ: ICAM-1 and CD11b inhibition worsen outcome in rats with E. coli
pneumonia. J Appl Physiol 1999; 87:299–307
40. Russo TA, Bartholomew LA, Davidson BA, Helinski JD, Carlino UB, Knight PR3rd, Beers MF, Atochina EN, Notter RH, Holm BA: Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol 2002; 283:L655–63
41. Satta G, Cornaglia G, Foddis G, Pompei R: Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa
, and Streptococcus pneumoniae
under in vitro
conditions simulating those of serious infections. Antimicrob Agents Chemother 1988; 32:552–60
42. West MA, Hackam DJ, Baker J, Rodriguez JL, Bellingham J, Rotstein OD: Mechanism of decreased in vitro
murine macrophage cytokine release after exposure to carbon dioxide: Relevance to laparoscopic surgery. Ann Surg 1997; 226:179–90
43. Coakley RJ, Taggart C, Greene C, McElvaney NG, O’Neill SJ: Ambient pCO2 modulates intracellular pH, intracellular oxidant generation, and interleukin-8 secretion in human neutrophils. J Leukoc Biol 2002; 71:603–10
44. Allen DB, Maguire JJ, Mahdavian M, Wicke C, Marcocci L, Scheuenstuhl H, Chang M, Le AX, Hopf HW, Hunt TK: Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Arch Surg 1997; 132:991–6
45. Coakley RJ, Taggart C, McElvaney NG, O’Neill SJ: Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood 2002; 100:3383–91
46. Doerr CH, Gajic O, Berrios JC, Caples S, Abdel M, Lymp JF, Hubmayr RD: Hypercapnic acidosis impairs plasma membrane wound resealing in ventilator-injured lungs. Am J Respir Crit Care Med 2005; 171:1371–7
47. Laffey JG, Engelberts D, Kavanagh BP: Buffering hypercapnic acidosis worsens acute lung injury. Am J Resp Crit Care Med 2000; 161:141–6
48. Laffey JG, Engelberts D, Duggan M, Veldhuizen R, Lewis JF, Kavanagh BP: Carbon dioxide attenuates pulmonary impairment resulting from hyperventilation. Crit Care Med 2003; 31:2634–40
49. Mori H, Kobayashi T, Shimizu S: Effect of carbon dioxide on growth of microorganisms in fed-batch cultures. J Ferment Technol 1983; 61:211–3
50. Reutershan J, Chang D, Hayes JK, Ley K: Protective effects of isoflurane pretreatment in endotoxin-induced lung injury. Anesthesiology 2006; 104:511–7
51. Stéphan F, Mabrouk N, Decailliot F, Delclaux C, Legrand P: Ventilator-associated pneumonia leading to acute lung injury after trauma: Importance of Haemophilus influenzae
. Anesthesiology 2006; 104:235–41
This article has been cited 11 time(s).
European Heart JournalEx vivo acidic preconditioning enhances bone marrow ckit cell therapeutic potential via increased CXCR4 expressionEuropean Heart Journal
Journal of Physiology-LondonCrossTalk proposal: There is added benefit to providing permissive hypercapnia in the treatment of ARDSJournal of Physiology-London
Journal of Physiology-LondonCrossTalk opposing view: There is not added benefit to providing permissive hypercapnia in the treatment of ARDS RebuttalJournal of Physiology-London
ThoraxHypercapnic acidosis attenuates pulmonary epithelial wound repair by an NF-kappa B dependent mechanismThorax
Faseb JournalElevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophageFaseb Journal
Blood PurificationMechanical Ventilation and the KidneyBlood Purification
Journal of Aerosol Medicine and Pulmonary Drug DeliveryOptimized Aerosol Delivery to a Mechanically Ventilated RodentJournal of Aerosol Medicine and Pulmonary Drug Delivery
Intensive Care MedicineHypercapnic acidosis in ventilator-induced lung injuryIntensive Care Medicine
Critical CareModerate and prolonged hypercapnic acidosis may protect against ventilator-induced diaphragmatic dysfunction in healthy piglet: an in vivo studyCritical Care
AnesthesiologyHypercapnic Acidosis: How Far?Anesthesiology
AnesthesiologyHypercapnia and Acidosis in Sepsis: A Double-edged Sword?Anesthesiology
© 2008 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.